AS 1403

Drug Profile

AS 1403

Alternative Names: TheraFab

Latest Information Update: 08 Sep 2003

Price : $50

At a glance

  • Originator Antisoma
  • Class Antineoplastics; Fab fragments; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lung cancer; Non-small cell lung cancer

Most Recent Events

  • 08 Sep 2003 Discontinued - Phase-I for Lung cancer in United Kingdom (IV)
  • 08 Sep 2003 Discontinued - Phase-I for Non-small cell lung cancer in Australia (IV)
  • 08 Sep 2003 Discontinued - Phase-I for Non-small cell lung cancer in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top